Unicycive Therapeutics, Inc.
UNCY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $675 | $951 | $0 |
| % Growth | -100% | -29% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $675 | $951 | $0 |
| % Margin | – | 100% | 100% | – |
| R&D Expenses | $20,014 | $12,902 | $12,436 | $6,080 |
| G&A Expenses | $12,103 | $8,547 | $6,567 | $2,897 |
| SG&A Expenses | $12,103 | $8,547 | $6,567 | $2,897 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $32,117 | $21,449 | $19,003 | $8,977 |
| Operating Income | -$32,117 | -$20,774 | -$18,052 | -$8,977 |
| % Margin | – | -3,077.6% | -1,898.2% | – |
| Other Income/Exp. Net | -$4,612 | -$9,770 | -$6 | -$1,040 |
| Pre-Tax Income | -$36,729 | -$30,544 | -$18,058 | -$10,017 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$36,729 | -$30,544 | -$18,058 | -$10,017 |
| % Margin | – | -4,525% | -1,898.8% | – |
| EPS | -5.6 | -1.28 | -1.2 | -8.6 |
| % Growth | -337.5% | -6.7% | 86% | – |
| EPS Diluted | -5.6 | -1.28 | -1.2 | -8.6 |
| Weighted Avg Shares Out | 6,699 | 2,454 | 1,506 | 1,168 |
| Weighted Avg Shares Out Dil | 6,699 | 2,454 | 1,506 | 1,168 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,261 | $615 | $0 | $0 |
| Interest Expense | $71 | $82 | $6 | $628 |
| Depreciation & Amortization | $428 | $284 | $161 | $13 |
| EBITDA | -$36,230 | -$30,178 | -$17,891 | -$9,376 |
| % Margin | – | -4,470.8% | -1,881.3% | – |